Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation

Young Hoon Jeong, Myeong Ki Hong, Cheol Whan Lee, Duk Woo Park, Young Hak Kim, Jae Joong Kim, Seong Wook Park, Seung Jung Park

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Higher rates of clinical and angiographic restenosis have been reported after coronary stenting in patients with significant chronic kidney disease (CKD). Whether drug-eluting stents (DES) can reduce long-term clinical events in CKD patients compared with bare metal stents (BMS) has not been established. Methods: The study enrolled 104 consecutive significant CKD patients (estimated creatinine clearance < 60 ml/min) treated with DES for 142 de novo coronary lesions, comprising 76 patients treated with sirolimus-eluting stents (SES) for 106 lesions and 28 patients treated with paclitaxel-eluting stents (PES) for 36 lesions. Data from these patients were compared to those from a control group comprising 50 patients treated with BMS during the preceding 1 year. Results: There were no differences in terms of baseline clinical characteristics except that the patients of the DES group were older, had a higher ratio of insulin treatment for diabetes mellitus, and had a more frequent history of previous percutaneous coronary intervention. The patients in the DES group had more unfavorable lesion characteristics with smaller reference vessel diameter (2.8 mm versus 3.3 mm; P < 0.001) and longer lesion length (28.8 mm versus 20.5 mm; P < 0.001) than those in the BMS group. Compared to BMS, DES implantation had a lower 1-year major adverse cardiac events rate (cardiac death, non-fatal myocardial infarction or target vessel revascularization) (12% versus 26%; P = 0.042). There were no significant differences between the SES and PES groups in terms of clinical outcomes. Conclusions: DES implantation for de novo coronary lesions in significant CKD patients reduces 1-year clinical events compared with BMS implantation.

Original languageEnglish
Pages (from-to)36-40
Number of pages5
JournalInternational Journal of Cardiology
Volume125
Issue number1
DOIs
Publication statusPublished - 2008 Mar 28

Fingerprint

Drug-Eluting Stents
Chronic Renal Insufficiency
Stents
Metals
Sirolimus
Paclitaxel
Percutaneous Coronary Intervention
Creatinine
Diabetes Mellitus
Myocardial Infarction
Insulin
Control Groups

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Jeong, Young Hoon ; Hong, Myeong Ki ; Lee, Cheol Whan ; Park, Duk Woo ; Kim, Young Hak ; Kim, Jae Joong ; Park, Seong Wook ; Park, Seung Jung. / Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. In: International Journal of Cardiology. 2008 ; Vol. 125, No. 1. pp. 36-40.
@article{67832dfe5f724fbca75355b1494f8a0e,
title = "Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation",
abstract = "Background: Higher rates of clinical and angiographic restenosis have been reported after coronary stenting in patients with significant chronic kidney disease (CKD). Whether drug-eluting stents (DES) can reduce long-term clinical events in CKD patients compared with bare metal stents (BMS) has not been established. Methods: The study enrolled 104 consecutive significant CKD patients (estimated creatinine clearance < 60 ml/min) treated with DES for 142 de novo coronary lesions, comprising 76 patients treated with sirolimus-eluting stents (SES) for 106 lesions and 28 patients treated with paclitaxel-eluting stents (PES) for 36 lesions. Data from these patients were compared to those from a control group comprising 50 patients treated with BMS during the preceding 1 year. Results: There were no differences in terms of baseline clinical characteristics except that the patients of the DES group were older, had a higher ratio of insulin treatment for diabetes mellitus, and had a more frequent history of previous percutaneous coronary intervention. The patients in the DES group had more unfavorable lesion characteristics with smaller reference vessel diameter (2.8 mm versus 3.3 mm; P < 0.001) and longer lesion length (28.8 mm versus 20.5 mm; P < 0.001) than those in the BMS group. Compared to BMS, DES implantation had a lower 1-year major adverse cardiac events rate (cardiac death, non-fatal myocardial infarction or target vessel revascularization) (12{\%} versus 26{\%}; P = 0.042). There were no significant differences between the SES and PES groups in terms of clinical outcomes. Conclusions: DES implantation for de novo coronary lesions in significant CKD patients reduces 1-year clinical events compared with BMS implantation.",
author = "Jeong, {Young Hoon} and Hong, {Myeong Ki} and Lee, {Cheol Whan} and Park, {Duk Woo} and Kim, {Young Hak} and Kim, {Jae Joong} and Park, {Seong Wook} and Park, {Seung Jung}",
year = "2008",
month = "3",
day = "28",
doi = "10.1016/j.ijcard.2007.02.026",
language = "English",
volume = "125",
pages = "36--40",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. / Jeong, Young Hoon; Hong, Myeong Ki; Lee, Cheol Whan; Park, Duk Woo; Kim, Young Hak; Kim, Jae Joong; Park, Seong Wook; Park, Seung Jung.

In: International Journal of Cardiology, Vol. 125, No. 1, 28.03.2008, p. 36-40.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation

AU - Jeong, Young Hoon

AU - Hong, Myeong Ki

AU - Lee, Cheol Whan

AU - Park, Duk Woo

AU - Kim, Young Hak

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Park, Seung Jung

PY - 2008/3/28

Y1 - 2008/3/28

N2 - Background: Higher rates of clinical and angiographic restenosis have been reported after coronary stenting in patients with significant chronic kidney disease (CKD). Whether drug-eluting stents (DES) can reduce long-term clinical events in CKD patients compared with bare metal stents (BMS) has not been established. Methods: The study enrolled 104 consecutive significant CKD patients (estimated creatinine clearance < 60 ml/min) treated with DES for 142 de novo coronary lesions, comprising 76 patients treated with sirolimus-eluting stents (SES) for 106 lesions and 28 patients treated with paclitaxel-eluting stents (PES) for 36 lesions. Data from these patients were compared to those from a control group comprising 50 patients treated with BMS during the preceding 1 year. Results: There were no differences in terms of baseline clinical characteristics except that the patients of the DES group were older, had a higher ratio of insulin treatment for diabetes mellitus, and had a more frequent history of previous percutaneous coronary intervention. The patients in the DES group had more unfavorable lesion characteristics with smaller reference vessel diameter (2.8 mm versus 3.3 mm; P < 0.001) and longer lesion length (28.8 mm versus 20.5 mm; P < 0.001) than those in the BMS group. Compared to BMS, DES implantation had a lower 1-year major adverse cardiac events rate (cardiac death, non-fatal myocardial infarction or target vessel revascularization) (12% versus 26%; P = 0.042). There were no significant differences between the SES and PES groups in terms of clinical outcomes. Conclusions: DES implantation for de novo coronary lesions in significant CKD patients reduces 1-year clinical events compared with BMS implantation.

AB - Background: Higher rates of clinical and angiographic restenosis have been reported after coronary stenting in patients with significant chronic kidney disease (CKD). Whether drug-eluting stents (DES) can reduce long-term clinical events in CKD patients compared with bare metal stents (BMS) has not been established. Methods: The study enrolled 104 consecutive significant CKD patients (estimated creatinine clearance < 60 ml/min) treated with DES for 142 de novo coronary lesions, comprising 76 patients treated with sirolimus-eluting stents (SES) for 106 lesions and 28 patients treated with paclitaxel-eluting stents (PES) for 36 lesions. Data from these patients were compared to those from a control group comprising 50 patients treated with BMS during the preceding 1 year. Results: There were no differences in terms of baseline clinical characteristics except that the patients of the DES group were older, had a higher ratio of insulin treatment for diabetes mellitus, and had a more frequent history of previous percutaneous coronary intervention. The patients in the DES group had more unfavorable lesion characteristics with smaller reference vessel diameter (2.8 mm versus 3.3 mm; P < 0.001) and longer lesion length (28.8 mm versus 20.5 mm; P < 0.001) than those in the BMS group. Compared to BMS, DES implantation had a lower 1-year major adverse cardiac events rate (cardiac death, non-fatal myocardial infarction or target vessel revascularization) (12% versus 26%; P = 0.042). There were no significant differences between the SES and PES groups in terms of clinical outcomes. Conclusions: DES implantation for de novo coronary lesions in significant CKD patients reduces 1-year clinical events compared with BMS implantation.

UR - http://www.scopus.com/inward/record.url?scp=39749098701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749098701&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2007.02.026

DO - 10.1016/j.ijcard.2007.02.026

M3 - Article

C2 - 17521753

AN - SCOPUS:39749098701

VL - 125

SP - 36

EP - 40

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -